QPS recently opened a second preclinical research facility in Taipei, Taiwan. The 2,793-square-foot facility will facilitate a research expansion into additional toxicology studies and a newly launched capability in pharmacology studies.
The new facility will be operational in December 2022 and will give QPS significant additional flexibility in study scheduling and additional space to grow the existing toxicology business and to build the new pharmacology unit.
Designed to ensure that the utmost care is taken with all toxicology and pharmacology studies, this new research facility boasts well equipped, fully accredited animal centers and a state-of-the-art pharmacology unit. Initially, the center will focus on augmenting the current multi-species capabilities in wound healing models, with pharmacology services in irritable bowel disease (IBD), non-alcoholic steatohepatitis (NASH) and atopic dermatitis. The team will be ready to conduct these studies in a variety of species in early 2023.
“Preclinical research across various species is a crucial step in the drug development process. Assessing toxicology and safety in these early stages of the research process helps to ensure that new drugs are safe enough to be allowed to progress to First in Human (FIH) clinical research trials” said Dr. Chen, Deputy General Manager & Head of the Center of Toxicology and Preclinical Sciences (CTPS) at QPS Taiwan.
QPS has hired Dr. Mei-Ling Hou, PhD to lead the new pharmacology department. Hou joins QPS from the Department of Pharmacology and Toxicology at the Institute for Drug Evaluation Platform, Development Center for Biotechnology (DCB). Dr. Hou’s expertise will strongly propel the growth and development of this new pharmacology service.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!